RU2761249C2 - Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile - Google Patents

Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile Download PDF

Info

Publication number
RU2761249C2
RU2761249C2 RU2019122099A RU2019122099A RU2761249C2 RU 2761249 C2 RU2761249 C2 RU 2761249C2 RU 2019122099 A RU2019122099 A RU 2019122099A RU 2019122099 A RU2019122099 A RU 2019122099A RU 2761249 C2 RU2761249 C2 RU 2761249C2
Authority
RU
Russia
Prior art keywords
allele
hla
tcdb
snp
drb1
Prior art date
Application number
RU2019122099A
Other languages
English (en)
Russian (ru)
Other versions
RU2019122099A3 (https=
RU2019122099A (ru
Inventor
Питер М. ШОУ
Деван В. МЕХРОТРА
Ребекка Л. БЛАНЧАРД
Цзюйдун ШЭНЬ
Робин МОГГ
Мэри Бет ДОРР
Цзюньхуа ЛИ
Сюнь СЮЙ
Original Assignee
Мерк Шарп энд Доум Корп.
Бэйцзин Геномикс Инститьют Эт Шэньчжэнь
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2016/109900 external-priority patent/WO2018107388A1/en
Application filed by Мерк Шарп энд Доум Корп., Бэйцзин Геномикс Инститьют Эт Шэньчжэнь filed Critical Мерк Шарп энд Доум Корп.
Publication of RU2019122099A publication Critical patent/RU2019122099A/ru
Publication of RU2019122099A3 publication Critical patent/RU2019122099A3/ru
Application granted granted Critical
Publication of RU2761249C2 publication Critical patent/RU2761249C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2019122099A 2016-12-14 2017-12-07 Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile RU2761249C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/109900 2016-12-14
PCT/CN2016/109900 WO2018107388A1 (en) 2016-12-14 2016-12-14 Human genetic markers associated with response to treatments that target clostridium difficile toxin b
US201762508066P 2017-05-18 2017-05-18
US62/508,066 2017-05-18
PCT/US2017/064985 WO2018111662A1 (en) 2016-12-14 2017-12-07 Human genetic markers associated with response to treatments that target clostridium difficile toxin b

Publications (3)

Publication Number Publication Date
RU2019122099A RU2019122099A (ru) 2021-01-15
RU2019122099A3 RU2019122099A3 (https=) 2021-04-16
RU2761249C2 true RU2761249C2 (ru) 2021-12-06

Family

ID=62559092

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019122099A RU2761249C2 (ru) 2016-12-14 2017-12-07 Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile

Country Status (9)

Country Link
US (1) US12071666B2 (https=)
EP (1) EP3555303B1 (https=)
JP (3) JP2020502179A (https=)
CN (1) CN110088300A (https=)
AU (1) AU2017375590A1 (https=)
BR (1) BR112019012203A2 (https=)
MX (1) MX2019007012A (https=)
RU (1) RU2761249C2 (https=)
WO (1) WO2018111662A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12071666B2 (en) * 2016-12-14 2024-08-27 Merck Sharp & Dohme Llc Human genetic markers associated with response to treatments that target clostridium difficile toxin B
CN112481395B (zh) * 2019-09-12 2024-10-18 深圳华大生命科学研究院 艰难梭菌耐药/低敏感进化分支snp标记及菌株类别鉴定方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA2044591C (en) 1989-02-13 2002-08-13 James Langham Dale Detection of a nucleic acid sequence or a change therein
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5302509A (en) 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
IL108159A (en) 1993-12-23 1998-02-08 Orgenics Ltd Apparatus for separation, concentration and detection of target molecules in liquid sample
EP0754240B1 (en) 1994-02-07 2003-08-20 Beckman Coulter, Inc. Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
AU710425B2 (en) 1995-12-18 1999-09-23 Washington University Method for nucleic acid analysis using fluorescence resonance energy transfer
ES2215241T3 (es) 1996-11-06 2004-10-01 Sequenom, Inc. Procedimiento de espectrometria de masa.
DE19782097T1 (de) 1996-11-06 1999-10-14 Sequenom Inc Zusammensetzungen und Verfahren zur Immobilisierung von Nucleinsäuren an feste Träger
JP2010522560A (ja) * 2007-03-27 2010-07-08 デューク ユニバーシティ Ｈｉｖ疾患制限に関連する遺伝的変異体
US20100035265A1 (en) 2008-07-18 2010-02-11 Aris Floratos Biomarkers for Drug-Induced Liver Injury
WO2010050829A1 (en) 2008-10-31 2010-05-06 Vialactia Biosciences (Nz) Limited Marker assisted selection of a mammalian subject for desired immunoglobulin phenotype
PE20120056A1 (es) 2009-02-24 2012-02-05 Merck Sharp & Dohme Derivados de indol como antagonistas del receptor crth2
HUE029098T2 (en) * 2009-08-21 2017-02-28 Novartis Ag To treat lapatinib cancer
SG10201701055WA (en) * 2011-09-16 2017-03-30 Ucb Pharma Sa Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
AU2012328524B2 (en) * 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
US10280470B2 (en) * 2013-01-11 2019-05-07 Baylor College Of Medicine Biomarkers of recurrent Clostridium difficile infection
EP3004386B1 (en) * 2013-05-29 2019-08-07 Immunexpress Pty Ltd Microbial markers and uses therefor
US9181632B1 (en) * 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
CN103665141B (zh) * 2013-12-31 2015-09-16 北京大学 与艰难梭菌细胞毒素b相互作用的蛋白
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US12071666B2 (en) * 2016-12-14 2024-08-27 Merck Sharp & Dohme Llc Human genetic markers associated with response to treatments that target clostridium difficile toxin B
WO2018107388A1 (en) 2016-12-14 2018-06-21 Merck Sharp & Dohme Corp. Human genetic markers associated with response to treatments that target clostridium difficile toxin b

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Deepika V. L. et al., Implications from predictions of HLA-DRB1 binding peptides in the membrane proteins of Corynebacterium diphtheriae, Bioinformation, 2008, Т. 3, No. 3, pp. 111. *
Deepika V. L. et al., Implications from predictions of HLA-DRB1 binding peptides in the membrane proteins of Corynebacterium diphtheriae, Bioinformation, 2008, Т. 3, No. 3, pp. 111. Schmitt-Egenolf M. et al., Oligonucleotide Typing Reveals Association of Type I Psoriasis with the HLA-DRB1* 0701/2,-DQA* 0201,-DQB1* 0303 Extended Haplotype, Journal of investigative dermatology, 1993, Т. 100, No. 6, pp. 749-752. Неретин В. Я. и др. HLA-DR, dq-генотипы и предрасположенность к миастении, Альманах клинической медицины 2001, номер. 4, стр. 176-178. Hernandez LD, Racine F, Xiao L, DiNunzio E, Hairston N, Sheth PR, Murgolo NJ, Therien AG. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling. Antimicrob Agents Chemother. 2015 Feb; 59(2):1052-60. doi: 10.1128/AAC.04433-14. Epub 2014 Dec 1. PMID: 25451052; PMCID: PMC4335902. *
Hernandez LD, Racine F, Xiao L, DiNunzio E, Hairston N, Sheth PR, Murgolo NJ, Therien AG. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling. Antimicrob Agents Chemother. 2015 Feb; 59(2):1052-60. doi: 10.1128/AAC.04433-14. Epub 2014 Dec 1. PMID: 25451052; PMCID: PMC4335902. *
Schmitt-Egenolf M. et al., Oligonucleotide Typing Reveals Association of Type I Psoriasis with the HLA-DRB1* 0701/2,-DQA* 0201,-DQB1* 0303 Extended Haplotype, Journal of investigative dermatology, 1993, Т. 100, No. 6, pp. 749-752. *
Неретин В. Я. и др. HLA-DR, dq-генотипы и предрасположенность к миастении, Альманах клинической медицины 2001, номер. 4, стр. 176-178. *

Also Published As

Publication number Publication date
EP3555303A4 (en) 2020-06-24
AU2017375590A1 (en) 2019-06-13
CN110088300A (zh) 2019-08-02
MX2019007012A (es) 2019-11-28
RU2019122099A3 (https=) 2021-04-16
JP2025061120A (ja) 2025-04-10
RU2019122099A (ru) 2021-01-15
JP2023055222A (ja) 2023-04-17
US20200017909A1 (en) 2020-01-16
WO2018111662A1 (en) 2018-06-21
EP3555303B1 (en) 2022-12-21
US12071666B2 (en) 2024-08-27
BR112019012203A2 (pt) 2019-11-12
EP3555303A1 (en) 2019-10-23
JP2020502179A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
TWI816927B (zh) 用於計算世系特異性之遺傳風險評分之媒體、方法及系統
US11674179B2 (en) Therapeutic regimen for hypertension
CA2989199A1 (en) Methods to diagnose and treat acute respiratory infections
JP2025061120A (ja) クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー
US20070065821A1 (en) Methods for the prediction of suicidality during treatment
IL303024A (en) Methods for identifying patients with an increased risk of developing a corona virus infection and treating it
Feng et al. Evidence of SARS-CoV-2 convergent evolution in immunosuppressed patients treated with antiviral therapies
WO2018107388A1 (en) Human genetic markers associated with response to treatments that target clostridium difficile toxin b
CN104937113A (zh) 用于预测由基于抗精神病药物的治疗诱导的锥体外系症状(eps)的发病的方法
US20080108076A1 (en) Genes associated with unipolar depression
US20060178843A1 (en) Genetic markers in the CSF2RB gene associated with an adverse hematological response to drugs
US20090281090A1 (en) Biomarkers for the prediction of responsiveness to clozapine treatment
US20060177860A1 (en) Genetic markers in the HLA-DQBI gene associated with an adverse hematological response to drugs
Hasan et al. Alternative genome sequencing approaches of SARS-CoV-2 using Ion AmpliSeq Technology
Getachew et al. High genetic diversity, clonal activation of hypnozoites and relapse of Plasmodium vivax isolates in low-transmission setting of Ethiopia
JP2026047651A (ja) 縄文祖先検査用バイオマーカー
WO2010033825A2 (en) Genetic variants associated with abdominal aortic aneurysms
Kanitwittaya et al. Genome-wide SNP-based linkage analysis of tuberculosis